In this single-center study, 69 patients with HCV antibody/HBs antigen-positive chronic liver disease were classified into two groups based on their SMI and compared for their microbiome and its predictive functional profiling. SMI was calculated based on the muscle mass area at the L3 vertebral level using the SYNAPSE VINCENT software (Fujifilm Medical, Tokyo, Japan). The microbiome was sequenced via MiSeq, and the results were compared with LEfSe32 (link) and PICRUSt233 .
The Research Ethics Committee of Nagoya University Hospital (protocol number 2015–0420, August 30, 2016) approved our research, and written informed consent was obtained from all patients before enrolment in accordance with the Declaration of Helsinki. This study was registered in the University Hospital Medical Information Network Clinical Trials Register (UMIN ID: 002,020,269). All clinical and stool sample information was anonymized, and a database was constructed.
The Research Ethics Committee of Nagoya University Hospital (protocol number 2015–0420, August 30, 2016) approved our research, and written informed consent was obtained from all patients before enrolment in accordance with the Declaration of Helsinki. This study was registered in the University Hospital Medical Information Network Clinical Trials Register (UMIN ID: 002,020,269). All clinical and stool sample information was anonymized, and a database was constructed.
Free full text: Click here
